相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
Alexis Fong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Microtubule-Targeting Drugs: More than Antimitotics
Roma Kaul et al.
JOURNAL OF NATURAL PRODUCTS (2019)
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Menetrier-Caux et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
Angela Flavia Serpico et al.
CANCERS (2019)
Orchestration of the spindle assembly checkpoint by CDK1-cyclin B1
Daniel Hayward et al.
FEBS LETTERS (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogens and Its Receptors Into Cancer Physiopathology
Mariana Segovia-Mendoza et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis
Weimei Ruan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii et al.
INVESTIGATIONAL NEW DRUGS (2018)
Recent advances in microtubule-stabilizing agents
Ya-Nan Cao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
Susanne Liewer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
The impact of mitotic errors on cell proliferation and tumorigenesis
Michelle S. Levine et al.
GENES & DEVELOPMENT (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton
Michel O. Steinmetz et al.
TRENDS IN CELL BIOLOGY (2018)
Nuclear envelope assembly defects link mitotic errors to chromothripsis
Shiwei Liu et al.
NATURE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Site occupancy calibration of taxane pharmacology in live cells and tissues
Javier J. Pineda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Darcy Bates et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Fighting tubulin-targeting anticancer drug toxicity and resistance
Roberta Visconti et al.
ENDOCRINE-RELATED CANCER (2017)
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic
Jue Shi et al.
ENDOCRINE-RELATED CANCER (2017)
EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis
Lucy S. K. Walker
IMMUNOLOGY LETTERS (2017)
G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells
Dani Kalsbeek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Taxol®: The First Microtubule Stabilizing Agent
Chia-Ping Huang Yang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Larissa Siqueira Penna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
Vinay Prasad et al.
SEMINARS IN ONCOLOGY (2017)
Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
T. J. Mitchison et al.
OPEN BIOLOGY (2017)
New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer
Ying Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Kemal Catakovic et al.
CELL COMMUNICATION AND SIGNALING (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Roberta Visconti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs
R. Visconti et al.
CELL DEATH AND DIFFERENTIATION (2015)
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
Marianne S. Poruchynsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Nab-paclitaxel: A flattering facelift
A. Viudez et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Interphase microtubules: chief casualties in the war on cancer?
Angela Ogden et al.
DRUG DISCOVERY TODAY (2014)
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver
MOLECULAR BIOLOGY OF THE CELL (2014)
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Katharine L. Sackton et al.
NATURE (2014)
Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles
Lauren M. Zasadil et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Kinesin Spindle Protein (KSP) Inhibitors in Combination with Chemotherapeutic Agents for Cancer Therapy
Hualong Song et al.
CHEMMEDCHEM (2013)
Mitosis and apoptosis: how is the balance set?
Caroline H. Topham et al.
CURRENT OPINION IN CELL BIOLOGY (2013)
Mitosis-targeting therapies: a troubleshooting guide
Elena Domenech et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
Edina Komlodi-Pasztor et al.
CLINICAL CANCER RESEARCH (2012)
DNA breaks and chromosome pulverization from errors in mitosis
Karen Crasta et al.
NATURE (2012)
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
Shan Wan et al.
PLOS ONE (2012)
Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit
Roberta Visconti et al.
NATURE COMMUNICATIONS (2012)
OPINION Mitosis is not a key target of microtubule agents in patient tumors
Edina Komlodi-Pasztor et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Mitotic catastrophe: a mechanism for avoiding genomic instability
Ilio Vitale et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
Xing Zeng et al.
CANCER CELL (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Novel formulations of taxanes: a review. Old wine in a new bottle?
KL Hennenfent et al.
ANNALS OF ONCOLOGY (2006)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
